Expression And Clinic Significance Of CD112and DDX3in Hepatocellular Carcinoma

BACKGROUND:There are many oncogenes, anti-oncogenes, proteins and enzymes acting in the occurrence and development of hepatocellular carcinoma (HCC). Nectin-2protein (also known as CD112) combined with the activated receptor CD226which is in NK cells and cytotoxic T lymphocyte (CTL)’surface, leading to activation of the biological functions of NK and CTL cells. It may be of important theoretical significance and application value in the anti-tumor immunity. Human DDX3is a ubiquitously expressed protein that belongs to the DEAD box family shown to possess RNA-unwinding and adenosine triphosphatase (ATPase) activities. Recent studies found that DDX3may be used as a potential tumor suppressor gene that plays a certain role in tumor occurrence and development process. However, what role in the occurrence and development of HCC and how it expresses in HCC is not very certain.The author studied the expression of CD112and DDX3in HCC, relationship between the expression and clinical pathological characterization and to find out the relationship between CD112and DDX3and prognosis of HCC through EnVisionTM immunohistochemistry.OBJECTIVE:to study the expression of CD112and DDX3in HCC, relationship between the expression and clinical pathological characterization and to find out the relationship between CD112and DDX3and prognosis of HCC.METHODS:The specimens from57patients with hepatocellular carcinoma(HCC) and15cases of adjacent noncancerous tissues (from the cancer≥3cm) were fixed in10%formalin and routinely embedded in paraffin. Tissue sections were stained by EnVisionTM immunohistochemistry with CD112as monoclonal antibody and DDX3as monoclonal antibody.The expression of CD112and DDX3in HCC, the relationship between the expression and clinical pathological characterization and the mean age in the positive group and negative group were studied with chi-square test,rank-sum test and Log-rank test analysis.RESULT:1.The positive expression rate of CD112in HCC tissues was66.67%(38/57), and it was significantly higher than that of normal liver tissues.(P<0.01). The rank mean of expression of CD112in HCC tissues was40.41, which was significantly higher than that of normal liver tissues.(P<0.01).2.The positive expression rate of DDX3in HCC tissues was54.39%(31/57), and it was significantly higher than that of normal liver tissues.(P<0.01). The rank mean of expression of DDX3in HCC tissues was40.22, which was significantly higher than that of normal liver tissues.(P<0.01). 3.In the clinical, pathological groups of HCC (including age, with or without hepatitis B, liver cirrhosis, serum alpha-fetoprotein level, histological differentiation, tumor diameter, portal vein tumor thrombus, with or without transfer), the positive expression rate and rank mean of CD112and DDX3has no obvious difference and statistically significant.(P>0.05).4. Use Log-rank test analysis found that The mean age in the CD112-positive group and CD112-negative group Was20.00±2.64and19.00±2.87month respectively, There Was no significant difference between the two groups (P>0.05), CD112expression level and hepatocellular carcinoma prognosis has no correlation.5.The mean age in the DDX3-positive group and DDX3-negative group Was18±1.86and16±1.28month respectively, There was no significant difference between the two groups (P>0.05), DDX3expression level and hepatocellular carcinoma prognosis has no correlation.6.The mean age in the common positive group and non-common negative group Was20±1.11and20±1.91month respectively, There was no significant difference between the two groups (P>0.05), the common expression of CD112and DDX3level and hepatocellular carcinoma prognosis has no correlation.CONCLUSION:1.The expression of CD112and DDX3in hepatocellular carcinoma tissues was higher than non-cancerous adjacent liver tissues;2.The expression levels of CD112, DDX3in hepatocellular carcinoma has no correlation with clinical, pathological features and prognosis of HCC patients.